Share This

The authors conducted a retrospective review of clinical / procedure documentation for consecutive blepharospasm (BEB) and hemifacial spasm (HFS) patients undergoing treatment with onabotulinum toxin A (Botox) in one clinic setting over the past 20 years. They report on the tolerance and long-term safety profiles of Botox treatment among Asian patients with benign essential BEB and HFS. Sample size totalled 105 patients with BEB (n=31) and HFS (n=74), all of whom were Asian. The mean follow-up was 84 (range 12-240) months and the mean number of sessions per patient was 19 (range 1-61). On review of dosage, the Botox dose per session increased significantly in both BEB (16.5 versus 21.6 units, p<0.05) and HFS (22.6 versus 26.9 units, p<0.05) patients after a mean of 18 sessions. However, onset time, effective duration and subjective treatment outcome were similar over time in both conditions. At least one local complication was reported among 26% and 41% of patients with BEB and HFS respectively, with ptosis (32%) being the most frequent. Local complications all self-resolved within six weeks post injection. This review allows clinicians to provide this patient group with a full and clear explanation of the potential tolerance of long-term botulinum toxin use.

A review of tolerance and safety profiles of long-term botulinum neurotoxin type a in Asian patients with hemifacial spasm and benign essential blepharospasm.
Lai KK, Tsang A, Kuk AK, et al.
Share This
Claire Howard

Salford Royal NHS Foundation Trust, Salford, UK.

View Full Profile